Cardiovascular safety of celecoxib in acute myocardial infarction patients: a nested case-control study

REVIEW, 17 December 2009
doi:10.5083/apjcm.20424906.11 , Cite or Link Using DOI
Creating a Digital Object Identifier Link

A digital object identifier (DOI) can be used to cite and link to electronic documents. A DOI is guaranteed never to change, so you can use it to link permanently to electronic documents.

To find a document using a DOI

  1. Copy the DOI of the document you want to open.
    The correct format for citing a DOI is as follows: doi:10.1016/S0140-6736(08)61345-8
  2. Open the following DOI site in your browser:
  3. Enter the entire DOI citation in the text box provided, and then click Go.
    The document that matches the DOI citation will display in your browser window.

The DOI scheme is administered by the International DOI Foundation. Many of the world's leading publishers have come together to build a DOI-based document linking scheme known as CrossRef.

Alain Vanasse, 1, 2 Artur J. de Brum-Fernandes,3 Josiane Courteau2

The objective was to measure the impact of exposure to coxibs and non-steroidal anti-inflammatory drugs (NSAID) on morbidity and mortality in older patients with acute myocardial infarction (AMI). A nested case-control study was carried out using an exhaustive population-based cohort of patients aged 66 years and older living in Quebec (Canada) who survived a hospitalization for AMI (ICD-9410) between 1999 and 2002. The main variables were all-cause and cardiovascular (CV) death, subsequent hospital admission for AMI, and a composite end-point including recurrent AMI or CV death. Conditional logistic regressions were used to estimate the risk of mortality and morbidity. A total of 19,823 patients aged 66 years and older survived hospitalization for AMI in the province of Quebec between 1999 and 2002. After controlling for covariables, the risk of subsequent AMI and the risk of composite end-point were increased by the use of rofecoxib. The risk of subsequent AMI was particularly high for new rofecoxib users (HR 2.47, 95% CI 1.57-3.89). No increased risk was observed for celecoxib users. No increased risk of CV death was observed for patients exposed to coxibs or NSAIDs. Patients newly exposed to NSAIDs were at an increased risk of death (HR 2.22,95% CI 1.30-3.77) and of composite end-point (HR 2.28, 95% CI 1.35-3.84). Users of rofecoxib and NSAIDs, but not celecoxib, were at an increased risk of recurrent AMI and of composite end-point. Surprisingly, no increased risk of CV death was observed. Further studies are needed to better understand these apparently contradictory results.

  1. Department of Family Medicine, Faculty of Medicine, Université de Sherbrooke, Sherbrooke (QC),Canada;
  2. PRIMUS Group, Clinical Research Centre, CHUS, Sherbrooke (QC), Canada; 3Department of Medicine, Faculty of Medicine, Université de Sherbrooke, Sherbrooke (QC), Canada

Correspondence to:
Alain Vanasse, Department of Family Medicine, Faculty of Medicine, Université de Sherbrooke 3001 12th Avenue North, Sherbrooke (Quebec) J1H 5N4, Canada.


cyclooxygenase-2, non-steroidal anti-inflammatory drugs, cardiovascular mortality, acute myocardial infarction